Market Overview

Bristol-Myers, Abbott Announce Results from Phase 2 Multiple Myeloma Study

Related BMY
Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate
Analyst: Nektar Has A Handful Of Milestones Ahead In 2018
Roche Rocks On With More Good News (Seeking Alpha)

Squibb Company (NYSE: BMY) and Abbott
(NYSE: ABT) today announced results from a small, randomized Phase 2,
open-label study in patients with previously-treated multiple myeloma
that evaluated two doses of elotuzumab (10 mg/kg and 20 mg/kg) in
combination with lenalidomide and low-dose dexamethasone. In the 10
mg/kg arm, median progression-free survival (PFS), or the time without
disease progression or death, was not reached after 20.8 months of
follow up (N=36) and the objective response rate (ORR) was 92%. Of
patients who received elotuzumab at a dose of 20 mg/kg, median PFS was
18.6 months (N=37) and ORR was 76%.

The safety data are consistent with previously-reported results for

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (ABT + BMY)

View Comments and Join the Discussion!

Partner Center